VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2020 | Update on the efficacy and safety of the LIBRETTO-531 trial

Mimi Hu, MD University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the results from the LIBERTTO-531 trial (NCT04211337). This study investigated the efficacy and safety of selpercatinib compared to a standard treatment in patients with rearranged during transfection (RET)- mutant medullary thyroid cancer (MCT) that is ineligible for surgery or metastatic. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter